Wenqun Zhang,Jing Yang,Chunju Zhou,Bo Hu,Ling Jin,Biping Deng,Yang Liu,Shan Wang,Alex H.Chang,Juan Du,Zifen Gao,Yonghong Zhang

TO THE EDITOR:

Burkitt lymphoma(BL)is a highly aggressive B-cell non-Hodgkin lymphoma(NHL),which accounts for 40%to 50%of pediatric NHL in nonendemic areas and~80%of pediatric B-NHL in the developed world.The prognosis for patients with BL has improved dramatically in the past few decades with the use of intensive short courses of non-cross-resistant chemotherapy agents determined by the patient risk stratification.The prognosis has been further improved by the recent introduction of rituximab.Nevertheless,the prognosis for pediatric patients with relapsed/refractory(r/r)BL remains dismal,with an average overall survival rate of 25%or lower.

Refer to the original:https://doi.org/10.1182/blood.2019002008